Vaxcyte (PCVX) Competitors

argenx (NASDAQ:ARGX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.

Which has higher valuation and earnings, ARGX or PCVX?

argenx has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx	$2.19B	16.73	-$295.05M	$12.59	47.91
Vaxcyte	N/A	N/A	-$402.27M	-$3.80	-18.86

Is ARGX or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to argenx's net margin of -2.11%. argenx's return on equity of -1.45% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenx	-2.11%	-1.45%	-1.29%
Vaxcyte	N/A	-23.53%	-22.20%

Do analysts rate ARGX or PCVX?

argenx presently has a consensus price target of $687.00, indicating a potential upside of 13.89%. Vaxcyte has a consensus price target of $147.50, indicating a potential upside of 105.82%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenx	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals have more ownership in ARGX or PCVX?

60.3% of argenx shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 2.4% of argenx shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more volatility & risk, ARGX or PCVX?

argenx has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.

Does the MarketBeat Community believe in ARGX or PCVX?

argenx received 605 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 76.56% of users gave Vaxcyte an outperform vote while only 67.28% of users gave argenx an outperform vote.

Company	Underperform	Outperform
argenx	Outperform Votes 654 67.28%	Underperform Votes 318 32.72%
Vaxcyte	Outperform Votes 49 76.56%	Underperform Votes 15 23.44%

Does the media refer more to ARGX or PCVX?

In the previous week, argenx had 19 more articles in the media than Vaxcyte. MarketBeat recorded 24 mentions for argenx and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.26 beat argenx's score of 1.04 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenx	12 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenx and Vaxcyte tied by winning 9 of the 18 factors compared between the two stocks.